RxDoctor Payments Data

S Subramony, MD

Neurology · Gainesville, FLNPI 1194739995

Payments from drug & device makers

$987,414in general payments, 2019–2025

Across 122 payments — averaging $8093.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$316K
  • PTC Therapeutics, Inc.$211K
  • Biogen$199K
  • Biohaven Pharmaceutical Holding Company Ltd.$93K
  • Biohaven Pharmaceuticals, Inc.$63K
  • Takeda Pharmaceuticals U.S.A., Inc.$34K
  • plus $72K from 7 others

What the payments were for

  • Consulting fees$13,14366%
  • Speaking & faculty fees$2,51213%
  • Travel & lodging$2,93915%
  • Food & beverage$1,2776%
  • Education$250%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$987,414 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$16,378
Medicare patients
95
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone39$1,145,997
PombilitiCipaglucosidase Alfa-Atga13$430,795
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$79,343
OpfoldaMiglustat13$2,603
Baclofen30$1,000
Gabapentin19$201
Risperidone12$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys$198,859$1,145,99739 claims
Amicus Therapeutics, Inc.Pombiliti, Opfolda$1,760$433,39826 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$33,915$79,34312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →